CGI vs Ricoh

CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems

CGI has been named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems, a significant industry recognition for the company's trade finance technology leadership.

10-Q Financial Filing Analysis for CGI (2026-07-29)

Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.

• Q2 2026 net product revenue rose 31.7% year-over-year to $256.1 million, bolstered by $47.6 million in initial sales from newly launched Lifyorli.
• Corcept resubmitted its New Drug Application (NDA) for relacorilant in endogenous Cushing's syndrome on June 17, 2026, establishing an FDA PDUFA target action date of December 17, 2026.
• The Court of Appeals affirmed a District Court ruling of non-infringement in the Teva patent litigation, with a petition for rehearing en banc denied in July 2026.

CGI Prices C$500 Million Senior Notes Offering

CGI Inc. has priced a private offering of C$500 million in senior unsecured notes, split equally between 3.25-year and 4.75-year maturities, with interest rates of 4.195% and 4.484% respectively. The offering is expected to close around September 14, 2026, and the net proceeds of approximately C$497.3 million will be used to repay existing indebtedness and for general corporate purposes. The notes are being offered in Canada on a private placement basis through a syndicate of agents led by major Canadian financial institutions including Scotiabank, Desjardins, BMO, CIBC, National Bank, RBC, and TD Securities. This financing move is part of CGI's capital management strategy to optimize its debt structure, reflecting the company's strong market position and liquidity management.

• CGI priced C$500 million in senior unsecured notes, split into two series of C$250 million each.
• The notes carry interest rates of 4.195% (3.25-year) and 4.484% (4.75-year).
• Net proceeds of ~C$497.3 million will be used for debt repayment and general corporate purposes.

Ricoh to construct new manufacturing facility in Japan to accelerate growth of its inkjet business

Ricoh announced plans to construct a new manufacturing facility in Japan to accelerate growth of its inkjet business. The announcement was made on 2026.09.18.

Ricoh named to TIME World's Best Companies 2026

Ricoh has been named to TIME's World's Best Companies 2026 list, recognizing its commitment to sustainability and corporate excellence.

Delivering Business Outcomes in the AI Era: Ricoh's Process-First Approach to AX

New Ricoh story (Event Report) covering Ricoh's process-first approach to automation transformation (AX) in the AI era, tied to a Gartner event. Also newly added: 'Beyond Integration: How ETRIA Is Shaping the Future Through Co-Creation' (2026.07.24, Ricoh's Initiatives).